Cerebral proteome adaptations to amyloid angiopathy are prevented by carbonic anhydrase inhibitors.

ABSTRACT:

Background

Cerebral amyloid angiopathy (CAA) is a hallmark of Alzheimer's disease (AD), linked to adverse effects of emerging AD treatments. We explored the molecular effects of CAA in mouse brain and evaluated how these could be prevented by two repurposed United States Food and Drug Administration (FDA) approved treatments.

Methods

Brain proteomics was performed on the Tg-SwDI genetic mouse model carrying disease causing mutations and developing AD characteristic cognitive deficits and severe CAA. Cortical and hippocampal tissues from presymptomatic male and female mice were studied.

Results

We identify a core of dysregulated proteins across studies, including established markers of AD as well as proteins indicative of astrogliosis and negative regulators of synapti

SUBMITTER: Carlsen J 

PROVIDER: S-EPMC12032195 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature